EUVIMEDEUVIMED entdecken
Open Access

Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool

Pauline Jeanjean, Abir Swaidan, Christopher Tse, Samantha Kwock, Iveta Fajnorova, Rachel Dove, Ines Camille Azrour, Sarah Taylor, Begonya Comin-Anduix, David A Nathanson, Giuseppe Carlucci, Jérémie Calais und 3 weitere

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.125.271759 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Pauline Jeanjean und 14 weiteren Autor:innen. Beteiligte Einrichtung: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, C…. Hauptthemen laut MEDLINE: Glioblastoma, Precision Medicine, Gelatinases, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma represents the most lethal form of brain cancer, characterized by a 5-y survival rate of approximately 4%. Fibroblast activation protein (FAP), expressed within both the tumor microenvironment and glioblastoma cells, has been identified as a promising therapeutic target. This study explores the potential of FAP-targeted molecular probes as theranostic agents for glioblastoma.

Methods

Human U-87 MG and murine SB28 glioblastoma-derived cell lines were used to establish immunodeficient and immunocompetent models, respectively. FAP inhibitor (FAPI)-46 was radiolabeled with 68Ga for imaging and 225Ac or 177Lu for therapy. Tumor uptake, therapeutic efficacy, immunomodulatory effects, and survival were evaluated for FAPI-46 alone or in combination with temozolomide in preclinical studies. [68Ga]Ga-FAPI-46 tumor uptake was also evaluated in patients.

Results

In subcutaneous xenografts, [68Ga]Ga-FAPI-46 exhibited high tumor uptake with minimal background signal. In the immunocompromised model, a single dose of [225Ac]Ac-FAPI-46 combined with temozolomide was sufficient to increase median survival, whereas in the immunocompetent model, 3 consecutive daily doses were required to achieve a significant survival benefit. [177Lu]Lu-FAPI-46 demonstrated lower therapeutic efficacy, as a monotherapy or in combination with temozolomide, than did [225Ac]Ac-FAPI-46. Immunomodulatory effects, assessed via flow cytometry, were insufficient to overcome the immunologically "cold" glioblastoma tumor microenvironment. In orthotopic xenografts and patients, [68Ga]Ga-FAPI-46 showed low uptake, indicating limited blood-brain barrier penetration and resulting in tumor concentrations likely too low for therapeutic efficacy.

Conclusion

FAPI-46 demonstrates significant potential as a theranostic agent for glioblastoma in peripheral models. However, its inability to cross the blood-brain barrier in orthotopic models highlights the need for future studies to improve its clinical applicability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaPrecision MedicineGelatinasesMembrane ProteinsBrain NeoplasmsTheranostic NanomedicineAnimalsHumansFibroblast Activation Protein AlphaEndopeptidasesMiceCell Line, TumorSerine EndopeptidasesFemaleGallium RadioisotopesMale

Stichwörter der Autor:innen

fibroblast activation proteinglioblastomaimmunomodulationtargeted radiopharmaceutical therapytheranostics

Substanzen

Fibroblast Activation Protein AlphaEndopeptidasesGelatinasesMembrane ProteinsSerine EndopeptidasesGallium Radioisotopes

Autor:innen und Institutionen

  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
  • Jonsson Comprehensive Cancer Center, UCLA Health, Los Angeles, California.
  • Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, California; and.
  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; cmona@mednet.ucla.edu elie@bessererlab.org.
  • California NanoSystems Institute, UCLA, Los Angeles, California.

Zitieren

APA

Jeanjean, P., Swaidan, A., Tse, C., Kwock, S., Fajnorova, I., Dove, R., Azrour, I. C., Taylor, S., Comin-Anduix, B., Nathanson, D. A., Carlucci, G., Calais, J., Czernin, J., Besserer-Offroy, É., & Mona, C. E. (2026). Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.271759

Vancouver

Jeanjean P, Swaidan A, Tse C, Kwock S, Fajnorova I, Dove R, et al. Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.271759

BibTeX
@article{Jeanjean2026,
  author = {Jeanjean, Pauline and Swaidan, Abir and Tse, Christopher and Kwock, Samantha and Fajnorova, Iveta and Dove, Rachel and Azrour, Ines Camille and Taylor, Sarah and Comin-Anduix, Begonya and Nathanson, David A and Carlucci, Giuseppe and Calais, Jérémie and Czernin, Johannes and Besserer-Offroy, Élie and Mona, Christine E},
  title = {Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.125.271759}
}
Kostenlos starten →